ImmPACT Bio USA is developing novel therapies that will improve current T-cell therapy by addressing the need to differentiate cancerous from non-cancerous tissues to increase safety and effectiveness
ImmPACT Bio USA is developing novel therapies that will improve current T-cell therapy by addressing the need to differentiate cancerous from non-cancerous tissues to increase safety and effectiveness.
The top three firms on F4's Biotech & Life Sciences investor list.